Loading
AbCellera
AbCellera, in Vancouver, finds antibodies that could become medicines by screening single immune cells at high speed. It does this for partner companies and for its own medicines, one of which is an antibody for an undisclosed cancer.
Also called: AbCellera Biologics
Overview
AbCellera Biologics, listed on Nasdaq as ABCL and based in Vancouver, describes a platform that integrates biology, computation and engineering to discover and develop antibody-based medicines, growing out of an academic lab where microfluidics and single-cell analysis were applied to antibody discovery. Carl Hansen is founding chief executive and Véronique Lecault is co-founder and chief technology officer. Its own pipeline lists ABCL635 (NK3R, vasomotor symptoms, phase 1/2), ABCL575 (OX40L, atopic dermatitis, phase 1 from the third quarter of 2025), ABCL688 (undisclosed, IND-enabling studies from the second quarter of 2025) and ABCL386, which the company describes as a potential antibody medicine for an undisclosed indication in oncology.
Notes
- Founding year not stated on the company pages read, so it is left out. The stage of ABCL386 is not stated clearly on the pipeline page. OnCo also mentions AbCellera as a founding partner of a startup in companies-startups.ts.
Connected
3fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
abcellera.com · 4
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/